• AstraZeneca published its third-quarter 2026 clinical trials update.
• Enhertu met the primary endpoint in the Phase III DESTINY-Lung04 trial for HER2-mutated advanced lung cancer.
• Tagrisso with Orpathys met primary endpoints in the Phase III SAFFRON and SANOVO lung cancer trials.
• Etcamah with palbociclib missed the primary endpoint in the Phase III SERENA-4 advanced breast cancer trial.
• Phase III data for Datroway's AVANZAR and TROPION-Lung15 lung cancer trials are expected in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.